Significance and Pathogenesis of Septic Shock

  • P. Brandtzaeg
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 216)

Abstract

Septic shock is a state of inadequate tissue perfusion induced by microbial products and characterized by low blood pressure and biochemical signs of oxygen deficit. The reduced oxygen and nutrient transport to vital organs is caused by a generalized intravascular inflammatory response resulting in vasodilation. Septic shock evolves through different stages and is initially characterized by a hyperdynamic circulation, i.e., high cardiac output and after volume loading low peripheral resistance (Parillo 1993). Most patients dying of septic shock remain in this circulatory state to the end (Parillo 1993). In patients with overwhelming bacteremia caused by Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and certain other bacteria the initial hyperdynamic circulation is gradually transformed into a hypodynamic circulation due to reduced cardiac performance. These patients die in a state of irreversible vasodilation combined with myocardial failure often with a terminal arrhythmia (Mercier et al. 1988; Brandtzaeg 1995).

Keywords

Septic Shock Vasoactive Intestinal Peptide Septic Shock Patient Meningococcal Disease Human Septic Shock 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen BM, Solberg O, Bryn K, Fröholm LO, Gaustad P, Høiby EA, Kristiansen BE, Bøvre K (1987) Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis 19:409–419.PubMedGoogle Scholar
  2. Behre G, Schedel I, Nentwig B, Wörmann B, Essink M, Hiddemann W (1992) Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of antiendotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother 36: 2139–2146.PubMedGoogle Scholar
  3. Benacerraf B, Seberstyen MM, Schlossman S (1959) A quantitative study of the kinetics of blood clearance of p32-labelled Escherichia coli and staphylococci by the reticuloendothelial system. J Exp Med 110:27–48.PubMedGoogle Scholar
  4. Bone R, Said S, Hiller C, Wilson F (1980) Vasoactive intestinal polypeptide in endotoxin shock. Am Rev Respir Dis 121: 113.Google Scholar
  5. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115: 457–469.PubMedGoogle Scholar
  6. Bone RC (1993) Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 6: 57–68.PubMedGoogle Scholar
  7. Brandtzaeg P (1995) Pathogenesis of meningococcal infections. In: Cartwrit K (ed) Meningococcal disease. Wiley, Chichester, pp 71–114.Google Scholar
  8. Brandtzaeg P, Kierulf P (1992) Endotoxin and meningococcemia. Intravascular inflammation induced by native endotoxin in man. In: Ryan JL, Morrison DC (eds) Immunopharmacology and pathophysiology. CRC Press, Boca Raton, pp 327–346 (Bacterial endotoxic eipopolysaccharides, vol 2)Google Scholar
  9. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E (1989a) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159: 195–204.PubMedGoogle Scholar
  10. Brandtzaeg P, Mollnes TE, Kierulf P (1989b) Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160: 58–65.PubMedGoogle Scholar
  11. Brandtzaeg P, Øktedalen O, Kierulf P, Opstad PK (1989c) Elevated VIP and plasma endotoxin in human gram-negative septic shock. Regul Pept 24: 37–44.PubMedGoogle Scholar
  12. Brandtzaeg P, Sandset M, Joø GB, Øvstebø R, Kierulf P, Abildgaard U (1989d) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55: 459–470.PubMedGoogle Scholar
  13. Brandtzaeg P, Joø GB, Brusletto B, Kierulf P (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57: 271–278.PubMedGoogle Scholar
  14. Brandtzaeg P, Bryn K, Kierulf P, øvstebø R, Namork E, Aase B, Jantzen E (1992) Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 89: 816–823.PubMedGoogle Scholar
  15. Brandtzaeg P, Øvstebø R, Kierulf P (1995) Bacteremia and compartmentalization of LPS in meningococcal disease. In: Levin J, Alving CR, Munford R, Redl H (eds) Lipopolysaccharides from genes to therapy. Wiley, New York pp 219–233.Google Scholar
  16. Brandtzaeg P, Osnes L, Øvstebø R, Joø GB, Westvik ÅB, Kierulf P (1996a) Net inflammatory capacity of human septic shock plasma evaluated by a monocyte based target cell assay. J Exp Med (inpress).Google Scholar
  17. Brandtzaeg P, Høgåsen K, Kierulf P, Mollnes TE (1996b) The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173:647–655.PubMedGoogle Scholar
  18. Brazilian Purpuric Fever study Group (1987) Epidemic purpura fulminans associated with antecedent purulent conjunctivitis. Lancet 2: 757–763.Google Scholar
  19. Burrell R (1994) Human responses to bacterial endotoxin. Circ Shock 43: 137–153.PubMedGoogle Scholar
  20. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, and the Swiss-Dutch J5 Immunoglobulin Study Group (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and Interferon-gamma in the serum of patients with septic shock. J Infect Dis 161: 982–987.PubMedGoogle Scholar
  21. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, and the Swiss-Dutch J5 Immunoglobulin Study Group (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 91: 23–29.PubMedGoogle Scholar
  22. Cannon JC, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Enders S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161: 79–84.PubMedGoogle Scholar
  23. Casale TB, Ballas ZK, Kaliner MA, Keahey TM (1990) The effect of intravenous endotoxin on various host-effector molecules. J Allergy Clin Immunol 85: 45–51.PubMedGoogle Scholar
  24. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771–778.PubMedGoogle Scholar
  25. Cavaillon JM, Pitton C, Fitting C (1994) Endotoxin tolerance is not a LPS-specific phenomenon: partial mimicry with IL-1, IL-10 and TGFβ. J Endotoxin Res 1: 21–29.Google Scholar
  26. Chetty C, Schwab JH (1987) Endotoxin-like products of grampositive bacteria. In: Rietschel ET (ed) Chemistry of endotoxin. Elsevier Amstrdam, pp 376–410 (Handbook of endotoxin, vol 1)Google Scholar
  27. Cochrane CG (1985) The contact activation system in septic shock In: Hinshaw LB (ed) Pathophysiology of endotoxin. Elsevier, Amsterdam, pp 286–298 (Handbook of endotoxin, vol 2)Google Scholar
  28. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor FB, Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91: 2850–2860.PubMedGoogle Scholar
  29. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parillo JE (1986) The coronary circulation in human septic shock. Circulation 73: 637–644.PubMedGoogle Scholar
  30. Da Silva AMT, Kaulbach HC, Chuidian FC, Lambert DR, Suffredini AF, Danner RL (1993) Shock and multiple organ dysfunction after self administration of Salmonella endotoxin. N Engl J Med 328:1457–1460.Google Scholar
  31. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975–978.PubMedGoogle Scholar
  32. Danner RL, Elin RL, Husseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99: 169–175.PubMedGoogle Scholar
  33. De Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJM, Hack CE, Taylor FB (1993) Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a bifasic activation pattern. Infect Immun 61: 4293–4301.Google Scholar
  34. De Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262: 249–251.Google Scholar
  35. Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17: 489–494.PubMedGoogle Scholar
  36. DeLa Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW (1993) Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 81: 3313–3317.Google Scholar
  37. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S (1995) High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171: 229–232.PubMedGoogle Scholar
  38. DeVoe IW, Gilchrist JE (1973) Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 138: 1156–1167.PubMedGoogle Scholar
  39. Dhainaut JF, Huyghebaert MF, Monsallier JF et al. (1987) Coronary hemodynamics and myocardial metabolism of lactate, free fatty acid, glucose, and ketones in patients with septic shock. Circulation 75: 533–541.PubMedGoogle Scholar
  40. Drake TA, Cheng J, Chang A, Taylor FB (1993) Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142: 1458–1470.PubMedGoogle Scholar
  41. Dziarski R (1993) The 70 kDa peptidoglycan/lipopolysaccharide receptor. In: Levin J, Alving CR, Munford RS, Stütz PL (eds) Bacterial endotoxin: recognition and effector mechanisms. Elsevier, Amsterdam, pp 151–165.Google Scholar
  42. Elin RJ, Wolff SM, McAdam KPWJ, Chedid L, Audibert F, Bernard C, Oberling F (1981) Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 144:329–336.PubMedGoogle Scholar
  43. Engebretsen LF, Kierulf P, Brandtzaeg P (1986) Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Tromb Res 42: 713–716.Google Scholar
  44. Fischer E, van Zee KJ, Marano MA, Rock CS, Kenny JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL (1992) lnterleukin-1-receptor antagonist circulates in experimental inflammation and in human disease. Blood 79: 2196–2200.PubMedGoogle Scholar
  45. Flegel WA, Wolpl A, Mannel DN, Northoff N (1989) Inhibition of endotoxin-induced activation of humanmonocytes by human lipoproteins. Infect Immun 57: 2237–2245.PubMedGoogle Scholar
  46. Fong Y, Moldawer LL, Marano M, Wei H, Tatter SB, Clarick RH, Santhanam U, Sherris D, May LT, Sehgal PB, Lowry SF (1989) Endotoxemia elicits increased circulating β2-INF/IL-6 in man. J Immunol 142: 2321–2324.PubMedGoogle Scholar
  47. Fong Y, Marano MA, Moldawer LL, Calvano SE, Kenny JS, Allison AC, Cerami A, Shires GT, Lowry SF (1990) The acute splancnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85: 1896–1904.PubMedGoogle Scholar
  48. Foreman NK, Wng WC, Cullen EJ, Stidham GL, Pearson TA, Shenep JL (1991) Endotoxic shock after transfusion of contaminated red blood cells in a child with sickle cell disease. Pediatr Infect Dis J 10:624–626.PubMedGoogle Scholar
  49. Frank MM, Fries LF (1988) The role of complement in defence against bacterial disease. Clin Immunol Allergy 2: 335–361.Google Scholar
  50. Freund H, Ebeid AM, Fischer JE (1981) An increase in vasoactive intestinal peptide levels in canine endotoxin shock. Surg Gynecol Obstet 152: 604–606.PubMedGoogle Scholar
  51. Furie B, Furie BC (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326: 800–806.PubMedGoogle Scholar
  52. Girardin E, Gray GE, Dayer JM, Roux-Lombard P, the J5 Study Group, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319: 397–400.PubMedGoogle Scholar
  53. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732–739.PubMedGoogle Scholar
  54. Glauser MP, Heumann D, Baumgartner JD, Cohen J (1994) Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 18: S205–S216.PubMedGoogle Scholar
  55. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA (1991) Production of interleukin-1-receptor antagonist during experimental endotoxinaemia. Lancet 228:1423–1424.Google Scholar
  56. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans J Immunol 151: 1637–1645.PubMedGoogle Scholar
  57. Guidet B, Barakett V, Vassal T, Petit JC, Offenstadt G (1994) Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 106: 1194–1201.PubMedGoogle Scholar
  58. Gurll HJ, Reynolds DG, Holaday JW (1988) Evidence for a role of endorphins in the cardiovascular pathophysiology of primate shock. Crit Care Med 16: 521–530.PubMedGoogle Scholar
  59. Hack CE, Nuijens JH, Felt-Bersma RJF, Schreuder WO, Eerenberg-Belmer AJM, Paardekooper J, Bronsveld W, Thijs LG (1989) Elevated plasma levels of anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. JAMA 86: 20–26.Google Scholar
  60. Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A (1993) lnterleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease 167: 471–475.Google Scholar
  61. Hangen DH, Stevens JH, Satoh PS, Hall EW, O’Hanley PT, Raffin T (1989) Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 46: 195–199.PubMedGoogle Scholar
  62. Hicklin H, Verghese A, Alvarez S (1987) Dysgonic fermenter 2 septicemia. Rev Infect Dis 9: 884–890.PubMedGoogle Scholar
  63. Høgåsen K, Mollnes TE, Brandtzaeg P (1994) Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal complement complex and vitronectin-thrombin-antithrombin complex. Infect Immun 62: 4874–4880.PubMedGoogle Scholar
  64. Hurley JC (1992) Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 15: 840–854.PubMedGoogle Scholar
  65. Jafari HS, McCracken GH (1992) Sepsis and septic shock: a review for clinicians. Pediatr Infect Dis J 11:739–749.PubMedGoogle Scholar
  66. Kierulf P, Andersen ÅBW (1990) Lipopolysaccharide-instructed, cryopreserved, human monocytes sequentially convert plasma fibrinogen to fibrin and lyse the fibrin formed. Pathobiology 59: 197–199.Google Scholar
  67. Kuhns DB, Alvord WG, Gallin Jl (1995) Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 171: 145–152.PubMedGoogle Scholar
  68. Levi M, ten Cate H, van der Poll T, van Deventer SJH (1993) Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 270: 975–979.PubMedGoogle Scholar
  69. Levin J, Poore TE, Zauber NP, Oser RS (1970) Detection of endotoxin in the blood of patients with sepsis due to gram-negative bacteria. N Engl J Med 283: 1313–1316.PubMedGoogle Scholar
  70. Levin J, Poore TE, Young NS, Margolis S, Zauber NP, Townes AS, Bell WR (1972) Gram-negative sepsis: detection of endotoxemia with the Limulus test. Ann Intern Med 76: 1–7.PubMedGoogle Scholar
  71. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC (1993) Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol 69: 136–142.PubMedGoogle Scholar
  72. Lynn WA, Cohen J (1995) Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 20: 143–158.PubMedGoogle Scholar
  73. Marchant A, Devière J, Byl B, De Groote D, Vincent JL, Goldman M (1994) Interleukin-10 production during septicaemia. Lancet 343: 707–708.PubMedGoogle Scholar
  74. Martich GD, Danner RL, Ceska M, Suffredini AF (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 173: 1021–1024.PubMedGoogle Scholar
  75. Martich GD, Boujoukos AJ, Suffredini AF (1993) Response of man to endotoxin. Immunobiology 187:403–416.PubMedGoogle Scholar
  76. Marty C, Misset B, Tamion F, Fitting C, Carlet J, Cavaillon JM (1994) Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and non septic origin. Crit Care Med 22: 673–679.PubMedGoogle Scholar
  77. McCabe WR (1973) Serum complement levels in bacteremias due to gram-negative organisms. N Engl J Med 288: 21–23.PubMedGoogle Scholar
  78. McCartney AC, Banks JG, Clements GB, Sleigh JD, Tehrani M, Ledingham IM (1983) Endotoxaemia in septic shock: clinical and post mortem correlations. Intensive Care Med 9: 117–122.PubMedGoogle Scholar
  79. Mercier JC, Beaufils F, Hartmann JF, Azéma D (1988) Hemodynamic patterns of meningococcal shock in children. Crit Care Med 16: 27–33.PubMedGoogle Scholar
  80. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SH, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481–1486.PubMedGoogle Scholar
  81. Monnoz C, Misset, B, Fitting C, Blériot JP, Cavaillon JM (1991) Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 21: 2177–2184.Google Scholar
  82. Moore FC, Moss NA, Revhaug A, Wilmore D, Mannick JA, Rodrick ML (1987) A single dose of endotoxin activates neutrophils without activating complement. Surgery 102: 200–205.PubMedGoogle Scholar
  83. Morrison DC (1990) Diversity of mammalian macromolecules which bind to bacterial lipopolysaccharides. In: Nowotny A, Spitser JJ, Ziegler EJ (eds) Cellular and molecular aspects of endotoxin reactions. Elseviers, Amsterdam, pp 183–189.Google Scholar
  84. Morrison DC, Ryan JL (1987) Endotoxins and disease mechanisms. Annu Rev Med 38: 417–432.PubMedGoogle Scholar
  85. Napolitano L, Chernow B (1988) Endorphins in circulatory shock. Crit Care Med 16: 566–567.PubMedGoogle Scholar
  86. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771–783.PubMedGoogle Scholar
  87. Nies AS, Forsyth RP, Williams HE, Melmon KL (1968) Contribution of kinins to endotoxin shock in unanathetizied rhesus monkeys. Circ Res 22: 155–164.PubMedGoogle Scholar
  88. Offner F, Vogelaers JPD, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Leroux-Roels G (1990) Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 116: 100–105.PubMedGoogle Scholar
  89. Østerud B, Flaegstad T (1983) Increased tissue tromboplastin activity in monocytes of patients with meningococcal infection: related to unfavourable prognosis. Thromb Haemostas 49: 5–7.Google Scholar
  90. Parillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471–1477.Google Scholar
  91. Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP (1990) Septic shock in humans. Ann Intern Med 113: 227–242.Google Scholar
  92. Petrak RA, Balk RA, Bone RC (1989) Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthesis inhibitors in the pathogenesis of multiple organ failure. Crit Care Clin 5: 303–314.PubMedGoogle Scholar
  93. Pinsky MR, Vincent JL, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Chest 103: 565–575.PubMedGoogle Scholar
  94. Pixley RA, DeLa Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB, Colman RW (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 91: 61–68.PubMedGoogle Scholar
  95. Pixley RA, Zellis S, Bankes P, DeLa Cadena PA, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW (1995) Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 23: 41–51.PubMedGoogle Scholar
  96. Proud D, Kaplan AP (1988) Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol 6: 49–83.PubMedGoogle Scholar
  97. Pruzanski W, Vadas P (1991) Phospholipase A2—a mediator between proximal and distal effectors of inflammation. Immunol Today 12: 143–146.PubMedGoogle Scholar
  98. Pruzanski W, Mackensen A, Engelhardt R, Stefanski E, Vadas P (1992) Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunother 12: 242–246.PubMedGoogle Scholar
  99. Revhaug A, Lugren I, Jenssen TG, Giercksky KE, Burhol PG (1988) Vasoactive intestinal peptide in sepsis and shock. Ann N Y Acad Sci 527: 536–545.PubMedGoogle Scholar
  100. Rietschel ET, Seydel U, Zähringer U, Schade UF, Brade L, Loppnow H, Feist W, Wang MH, Ulmer AJ, Flad HD, Brandenburg K, Kirikae T, Grimmecke D, Holst O, Brade H (1991) Bacterial endotoxin: molecular relationship between structure and activity. Infect Dis Clin North Am 5: 753–779.PubMedGoogle Scholar
  101. Shands JW, McKinney C (1989) Plasma endotoxin: increased levels in neutropenic patients do not correlate with fever. J Infect Dis 159: 777–780.PubMedGoogle Scholar
  102. Spinas GA, Bloesch D, Kaufmann MT, Keller U, Dayer JM (1990) Induction of plasma inhibitors of interleukin 1 and TNF-α activity by endotoxin administration to normal humans. Am J Physiol 259:R993–R997.PubMedGoogle Scholar
  103. Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533–536.PubMedGoogle Scholar
  104. Spitznagel JK (1990) Antibiotic proteins of human neutrophils. J Clin Invest 86: 1381–1386.PubMedGoogle Scholar
  105. Sprung CL, Schultz DR, Marcial E, Caralis PV, Gelbard MA, Arnold PI, Long WM (1986) Complement activation in septic shock patients. Crit Care Med 14: 525–528.PubMedGoogle Scholar
  106. Suffredini AF, Harpel PC, Parrillo JE (1989a) Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165–1172.PubMedGoogle Scholar
  107. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE (1989b) The cardiovascular response of humans to the administration of endotoxin. N Engl J Med 321: 280–287.PubMedGoogle Scholar
  108. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parrillo JE (1992) Pulmonary and oxygen transport effects on intravenously administered endotoxin in normal humans. Am Rev Respir Dis 145: 1398–1403.PubMedGoogle Scholar
  109. Taylor FB, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918–925.PubMedGoogle Scholar
  110. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE (1988) Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26: 227–235.PubMedGoogle Scholar
  111. Taylor FB, Chang A, Ruf W, Morrisey JH, Hinshaw L, Catlett R, Blick K, Edgington TS (1991) Lethal E. oli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127–135.PubMedGoogle Scholar
  112. Tracey KJ, Fong Y, Hesse Dg, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664.PubMedGoogle Scholar
  113. Vadas P, Pruzanski W, Stefanski E, Sternby B, Mustard R, Bohnen J, Fraser I, Farewell V, Bombardier C (1988) Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med 16: 1–7.PubMedGoogle Scholar
  114. Van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW (1990) Activation of the coagulation after administration of tumor necrosis factor to nornal subjects. N Engl J Med 322: 1622–1627.PubMedGoogle Scholar
  115. Van der Poll T, Romijn JA, Endert E, Borm JJJ, Büller HR, Sauerwein HP (1991a) Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261: E457–E465.PubMedGoogle Scholar
  116. Van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW (1991b) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174: 729–732.PubMedGoogle Scholar
  117. Van der Poll T, van Deventer SJH, Büller HR, Sturk A, ten Cate JW (1991c) Comparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. J Infect Dis 164: 599–601.PubMedGoogle Scholar
  118. Van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Büller HR, ten Cate JW (1992) Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 79:693–698.PubMedGoogle Scholar
  119. Van Deuren M, van der Ven-Jongekrijg J, Demacker PNM, Bartelink Akm, van Dalen R, Sauerwein RW, Gallati H, Vannice JL, van der Meer JWM (1994) Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 169:157–161.PubMedGoogle Scholar
  120. Van Deventer SJH, Buller H, ten Cate JW, Sturk A, Pouw W (1988) Endotoxaemia: an early predictor of septicemia in febrile patients. Lancet 1: 605–609.PubMedGoogle Scholar
  121. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack E, Sturk A (1990) Experimental endotoxinemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520–2526.PubMedGoogle Scholar
  122. Van Deventer SJH, Hart M, van der Poll T, Hack CE, Aarden LA (1993) Endotoxin and tumor necrosis factor-a-induced interleukin-8 release in humans. J Infect Dis 167: 461–464.PubMedGoogle Scholar
  123. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sei USA 89: 4845–4849.Google Scholar
  124. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HSA, Stiles DM, Pribble J, Catalano M, Moldawer LL, Lowry SF (1995) Influence of IL-1 receptor blockade on the human response to endotoxinemia. J Immunol 154: 149–1507.Google Scholar
  125. Waage A, Aasen AO (1992) Different role of cytokin mediators in septic shock related to meningococcal disease and surgery/polytrauma. Immunol Rev 127: 221–230.PubMedGoogle Scholar
  126. Waage A, Halstensen A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1: 355–357.PubMedGoogle Scholar
  127. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 169: 33–38.Google Scholar
  128. Waage A, Halstensen A, Espevik T, Brandtzaeg P (1994) Cytokines in meningococcal disease. Baillières Clin Infect Dis 1: 97–108.Google Scholar
  129. Waring PM, Waring JL, Metcalf D (1994) Circulating leukemia inhibiting factor levels correlate with disease severity in meningococcemia. J Infect Dis 170: 1224–1228.PubMedGoogle Scholar
  130. Whaley K, Khong TY, McCartney AC, Ledingham IM (1979) Complement activation and its control in gram negative endotoxic shock. J Clin Lab Immunol 2: 117–124.Google Scholar
  131. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431–1433.PubMedGoogle Scholar
  132. Young LS, Proctor RA, Beutler B, McCabe WR, Sheagren JN (1991) University of California/Davis interdepartmental conference on gram-negative septicemia. Rev Infect Dis 13: 666–687.PubMedGoogle Scholar
  133. Zabel P, Wolter DT, Schönharting MM, Schade UF (1989) Oxpentifyllin in endotoxaemia. Lancet 2: 1474–1477.PubMedGoogle Scholar
  134. Zumla A (1992) Superantigens, T cells and microbes. Clin Infect Dis 15: 313–320.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • P. Brandtzaeg
    • 1
  1. 1.Department of Pediatrics and Clinical ChemistryUllevål University HospitalOsloNorway

Personalised recommendations